Remove Food and Drug Administration Remove Leads Remove Physicians Remove Transportation
article thumbnail

Delivery systems for biologics

European Pharmaceutical Review

1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

article thumbnail

Untapped opportunity: the growing potential of clinical trials in Georgia

Pharmaceutical Technology

Another factor driving Georgia’s growth in the clinical trial space is the recent significant investment in the country’s health system, creating several new facilities and programmes, as well as increasing the number of experienced physicians.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The FDA now recommends that clinical trial sponsors submit a Race and Ethnicity Diversity Plan

Clarify Health

The US Food and Drug Administration (FDA) recently announced new draft guidance for life science companies on increasing diversity and inclusion in clinical trials to improve enrollments of underrepresented racial and ethnic populations.

FDA 52
article thumbnail

The FDA now recommends that clinical trial sponsors submit a Race and Ethnicity Diversity Plan

Clarify Health

The US Food and Drug Administration (FDA) recently announced new draft guidance for life science companies on increasing diversity and inclusion in clinical trials to improve enrollments of underrepresented racial and ethnic populations.

FDA 52